Premium
Costo‐efectividad del artesunato para el tratamiento de la malaria severa
Author(s) -
Lubell Y.,
Yeung S.,
Dondorp A. M.,
Day N. P.,
Nosten F.,
Tjitra E.,
Abul Faiz Md.,
Bin Yunus E.,
Anstey N.M.,
Mishra S.K.,
Mohanty S.,
White N.J.,
Mills A.J.
Publication year - 2009
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/j.1365-3156.2009.02227.x
Subject(s) - artesunate , severe malaria , malaria , medicine , quinine , artemisinin , intensive care medicine , plasmodium falciparum , immunology
Summary Objective To explore the cost‐effectiveness of artesunate against quinine based principally on the findings of a large multi‐centre trial carried out in Southeast Asia. Methods Trial data were used to compare mortality of patients with severe malaria, treated with either artesunate or quinine. This was combined with retrospectively collected cost data to estimate the incremental cost per death averted with the use of artesunate instead of quinine. Results The incremental cost per death averted using artesunate was approximately 140 USD. Artesunate maintained this high level of cost‐effectiveness also when allowing for the uncertainty surrounding the cost and effectiveness assessments. Conclusion This analysis confirms the vast superiority of artesunate for treatment of severe malaria from an economic as well as a clinical perspective.